CN Patent

CN120518763A — 针对利拉鲁肽的抗体及其用途

Assigned to Novo Nordisk AS · Expires 2025-08-22 · 1y expired

What this patent protects

本发明涉及特异性抗体及其用途，例如用于鉴定和/或量化利拉鲁肽原纤维和/或司美格鲁肽原纤维。

USPTO Abstract

本发明涉及特异性抗体及其用途，例如用于鉴定和/或量化利拉鲁肽原纤维和/或司美格鲁肽原纤维。

Drugs covered by this patent

Patent Metadata

Patent number
CN120518763A
Jurisdiction
CN
Classification
—
Expires
2025-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.